Oral antibiotic therapy for acne vulgaris: Pharmacokinetic and pharmacodynamic perspectives

Journal of Clinical and Aesthetic Dermatology

Volumn 4, Issue 2, 2011, Pages 40-47

  Leyden, James J ^a   del Rosso, James Q ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VALLEY HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; CALCIUM; DOXYCYCLINE; ERYTHROMYCIN; IRON; MAGNESIUM; MINOCYCLINE; TETRACYCLINE;

ACNE VULGARIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AUTOIMMUNE DISEASE; BACTERIAL STRAIN; BODY WEIGHT; CENTRAL NERVOUS SYSTEM DISEASE; DIETARY INTAKE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TISSUE LEVEL; ESOPHAGUS INJURY; FOOD; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HUMAN; HYPERPIGMENTATION; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; PROPIONIBACTERIUM ACNES; REVIEW; SEBUM; SKIN MANIFESTATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 79951607957     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Dreno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004;14:391-399.
2. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60:S1-S50.
3. Leyden JJ. Therapy for acne vulgaris. N Engl J Med. 1997;336:1156-1162.
4. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49:S1-S37.
5. Del Rosso JQ, Kim G. Optimizing use of oral antibiotics in acne vulgaris. Dermatol Clin. 2009;27:33-42.
6. Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003;121:20-27.
7. Mouser PE, Baker BS, Seaton ED, Chu AC. Propionibacterium acnes-reactive T helper-1 cells in the skin of patients with acne vulgaris. J Invest Dermatol. 2003;121:1226-1228.
8. Webster GF. Acne vulgaris. BMJ. 2002;325:475-479.
9. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-265.
10. Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin. 2007;25:133-135, v.
11. Ochsendorf F. Systemic antibiotic therapy of acne vulgaris. J Dtsch Dermatol Ges. 2006;4:828-841.
12. Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2003:CD002086.
13. Fleischer AB, Jr., Dinehart S, Stough D, Plott RT. Safety and efficacy of a new extended-release formulation of minocycline. Cutis. 2006;78:21-31.
14. Stewart DM, Torok HM, Weiss JS, Plott RT. Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Cutis. 2006;78:11-20.
15. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58:256-265.
16. Oracea™ (doxycycline, USP). Full Prescribing Information, CollaGenex Pharmaceuticals, Inc., Newtown, PA, 2006.
17. Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60: 717-733.
18. Fleisher D, Li C, Zhou Y, et al. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet. 1999;36:233-254.
19. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11-23.
20. Gollnick HP, Finlay AY, Shear N. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol. 2008;9:279-284.
21. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27:1329-1342.
22. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998;279:365-370.
23. Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest. 1999;115: 19S-23S.
24. Crawford WW, Crawford IP, Stoughton RB, Cornell RC. Laboratory induction and clinical occurrence of combined clindamycin and erythromycin resistance in Coryne-bacterium acnes. J Invest Dermatol. 1979;72:187-190.
25. Gump DW, Ashikaga T, Fink TJ, Radin AM. Side effects of minocycline: different dosage regimens. Antimicrob Agents Chemother. 1977;12:642-646.
26. Lennernas H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica. 2007;37:1015-1051.
27. Del Rosso J. Clinical significance of brand versus generic formulations: focus on oral minocycline. Cutis. 2006;77: 153-156.
28. Leyden JJ, Kaidbey K, Gans EH. The antimicrobial effects in vivo of minocycline, doxycycline and tetracycline in humans. J Dermatol Treat. 1996;7:223-225.
29. Plott RT, Wortzman MS. Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. Cutis. 2006;78:6-10.
30. O'Neil MJ, Smith A, Heckelman PE, Budavari S. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th ed. Hoboken, NJ: John Wiley & Sons; 2001.
31. Fabre J, Milek E, Kalfopoulos P, Merier G. [Tetracycline kinetics in man. Digestive absorption and serum concentration]. Schweiz Med Wochenschr. 1971;101: 593-598.
32. Leyden JJ. Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron. J Am Acad Dermatol. 1985;12:308-312.
33. Welling PG, Koch PA, Lau CC, Craig WA. Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrob Agents Chemother. 1977;11:462-469.
34. Neuvonen PJ. Interactions with the absorption of tetracyclines. Drugs. 1976;11:45-54.
35. Cunha BA, Garabedian-Ruffalo SM. Tetracyclines in urology: current concepts. Urology. 1990;36:548-556.
36. Gnarpe H, Dornbusch K, Hagg O. Doxycycline concentration levels in bone, soft tissue and serum after intravenous infusion of doxycycline. A clinical study. Scand J Infect Dis Suppl. 1976:54-57.
37. Smith C, Woods CG, Woods MJ. Absorption of minocycline. J Antimicrob Chemother. 1984;13:93.
38. ® [package insert]. Scottsdale, AZ: Medicis, The Dermatology Company; 2010.
39. Macdonald H, Kelly RG, Allen ES, et al. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther. 1973;14:852-861.
40. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the USA, Japan and Australia. Br J Dermatol. 2001;144:339-346.
41. Data on File (NDA 50-808; Section 2.7.6.4). Medicis Pharmaceutical Corporation, Scottsdale, AZ; 2006.
42. Data on File (NDA 50-808; Section 2.7.6.2; Study AAI-US-190). Medicis Pharmaceutical Corporation, Scottsdale, AZ; 2006.
43. Data on File (NDA 50-808; Section 3.2.P.8.3). Medicis Pharmaceutical Corporation, Scottsdale AZ; 2006